Descriptive Epidemiology of Hospitalization of Patients with a Rare Tumor in an Italian Region

Objectives: Rare tumors (RT) collectively account for one quarter of all malignancies in Italy. The low frequency and the large heterogeneity in natural history and outcome of individual diseases, together with a scarcity of epidemiological information make them a challenge for clinical practice, as well as for public healthcare organizations. We conducted a retrospective study to quantify the burden of hospitalization in a real-word setting in patients diagnosed with these diseases in an Italian region. Methods: RT patients were tracked along all hospital stays from 2000 to 2019 using hospital discharge records. Frequency of hospitalizations, average time spent in hospital and median timespan between consecutive admissions were considered. Re-hospitalization rates were analyzed through a multivariable negative binomial regression analysis to adjust for confounding and allowing for over-dispersion in count data. Results: As a whole, 57,329 patients were identified at first stay for all studied tumors. A total of 183,959 admissions were retrieved, along a median of 3 hospitalizations per patient. Median timespan between hospitalizations shortened in the course of the study years (12.5 months in 2000–2004 to 5.4 months in 2015–2019). The overall re-hospitalization rate increased from 0.92 per patient/year (95% CI = 0.81–1.04) in 2000–2004 to 2.17 (95% CI = 1.90–2.47) in 2015–2019. Conclusions: Overall, the hospitalization rate of patients with a RT increased in the twenty years since the 2000 and particularly doubled starting from 2015. A higher burden of hospitalizations was found for tumors of the central nervous system, thoracic cavity, digestive tract and sarcomas. To the best of our knowledge this is the first paper related to access to Italian healthcare facilities of patients with these tumors.

[1]  F. Petrelli,et al.  Efficacy of Immune Checkpoint Inhibitors in Rare Tumours: A Systematic Review , 2021, Frontiers in Immunology.

[2]  J. Wisnivesky,et al.  Effect of treatment center volume on outcomes in gastroenteropancreatic neuroendocrine tumor patients , 2018, BMC Cancer.

[3]  P. Casali,et al.  Rationale of the rare cancer list: a consensus paper from the Joint Action on Rare Cancers (JARC) of the European Union (EU) , 2020, ESMO Open.

[4]  G. Tagliabue,et al.  Epidemiology and biological characteristics of male breast cancer in Italy , 2020, Breast Cancer.

[5]  G. Gatta,et al.  Where Are Adolescents with Soft Tissue Sarcomas Treated? An Italian Nationwide Study on Referrals Based on Hospital Discharge Records. , 2020, Journal of adolescent and young adult oncology.

[6]  D. Taruscio,et al.  A National Hospital‐Based Study of Hospitalized Patients With Primary Biliary Cholangitis , 2019, Hepatology communications.

[7]  D. Serraino,et al.  Sensitivity and specificity of breast cancer ICD-9-CM codes in three Italian administrative healthcare databases: a diagnostic accuracy study , 2018, BMJ Open.

[8]  D. Serraino,et al.  Accuracy of colorectal cancer ICD-9-CM codes in Italian administrative healthcare databases: a cross-sectional diagnostic study , 2018, BMJ Open.

[9]  D. Serraino,et al.  Validating malignant melanoma ICD-9-CM codes in Umbria, ASL Napoli 3 Sud and Friuli Venezia Giulia administrative healthcare databases: a diagnostic accuracy study , 2018, BMJ Open.

[10]  Jesse S Boehm,et al.  Emerging Opportunities for Target Discovery in Rare Cancers. , 2017, Cell chemical biology.

[11]  Eva Ardanaz,et al.  Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. , 2017, The Lancet. Oncology.

[12]  R. K. Pillai,et al.  Rare cancers: Challenges & issues , 2017, The Indian journal of medical research.

[13]  John P. A. Ioannidis,et al.  What does research reproducibility mean? , 2016, Science Translational Medicine.

[14]  G. Gatta,et al.  Italian cancer figures--Report 2015: The burden of rare cancers in Italy. , 2016, Epidemiologia e prevenzione.

[15]  G. Gatta,et al.  Methodological aspects of estimating rare cancer prevalence in Europe: the experience of the RARECARE project. , 2013, Cancer epidemiology.

[16]  T. Trimble,et al.  International rare cancers initiative. , 2013, The Lancet. Oncology.

[17]  Martijn J Schuemie,et al.  Chronic disease prevalence from Italian administrative databases in the VALORE project: a validation through comparison of population estimates with general practice databases and national survey , 2013, BMC Public Health.

[18]  G. Eslick What is a Rare Cancer? , 2012, Hematology/oncology clinics of North America.

[19]  A. Giordano,et al.  The burden of breast cancer in Italy: mastectomies and quadrantectomies performed between 2001 and 2008 based on nationwide hospital discharge records , 2012, Journal of experimental & clinical cancer research : CR.

[20]  G. Gatta,et al.  The Burden of Rare Cancers in Italy: The Surveillance of Rare Cancers in Italy (RITA) Project , 2012 .

[21]  G. Gatta,et al.  The burden of rare cancers in Italy: the surveillance of rare cancers in Italy (RITA) project. , 2012, Tumori.

[22]  G. Gatta,et al.  Rare cancers are not so rare: the rare cancer burden in Europe. , 2011, European journal of cancer.

[23]  H. Howe,et al.  The Occurrence of Rare Cancers in U.S. Adults, 1995–2004 , 2010, Public health reports.

[24]  Gemma Gatta,et al.  The burden of rare cancers in Europe. , 2010, Advances in experimental medicine and biology.

[25]  E. Faerstein,et al.  A DICTIONARY OF EPIDEMIOLOGY , 2016 .

[26]  J. Hilbe Negative Binomial Regression: Preface , 2007 .

[27]  E. Steliarova-Foucher,et al.  Cancer in children and adolescents in Europe: developments over 20 years and future challenges. , 2006, European journal of cancer.

[28]  K. Dear,et al.  Strategy for randomised clinical trials in rare cancers , 2003, BMJ : British Medical Journal.

[29]  Very rare cancers--a problem neglected. , 2001, The Lancet. Oncology.